Therefore, the potential of this agent to elicit HER-independent activity was of particular interest to explore in the CRC setting, where patients often exhibit resistance to cetuximab and other EGFR or HER2 targeted agents. The gene discussed is ERBB2; the disease is colorectal carcinoma.